Latest ArticlesAt present, many active pharmaceutical ingredients have not been developed in formulations due to their low aqueous solubilities, which cause low bioavailabilities of drugs. Therefore, improving the solubility and bioavailability of drugs is an important challenge in preparation research. The transformation of drugs from crystalline state to amorphous state can greatly increase the solubility, resulting in higher dissolution rate and bioavailability. Understanding and mastering the glass-forming ability(GFA) of drugs(namely the transformation ability of a crystalline compound to an amorphous state) and their influence factors are the basis for judging the suitability of preparation of amorphous drugs. Therefore, this review analyzes the influence factors of GFA from the aspects of drug structure, thermodynamic properties, kinetic properties and external environment. The methods to evaluate GFA of drugs are also summarized. It is hoped to provide a reference for the development and design of amorphous preparations.
Orally inhaled drug products are a combination of aerosol generating devices with different principles and corresponding drug forms. It is the first-choice therapy for prevention and treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease(COPD). Orally inhaled drug products not only have technical challenges in the formulation development, but also have many difficulties in their use. This study summarizes the recent research progress of orally inhaled drug products in improving patient compliance, overcoming delivery dose limitations, improving atomization by controlling particle characteristics, and expanding the scope of treatment, as well as the development of relevant regulations and guidelines. The innovations in process, formulation, device, standard and treatment field are reviewed, hoping to provide some references for researches on orally inhaled products.
Ginkgo biloba L. is rich in shikimic acid. Modern pharmacological studies have shown that shikimic acid has antioxidant, antithrombotic, antibacterial and anti-inflammatory activities. It is the raw material for the synthesis of oseltamivir phosphate, an anti-avian influenza and anti-influenza A(H1N1) virus drug. At present, many researchers engage in expanding the sources of shikimic acid and synthesizing compounds with anticancer, antiviral and glycemic control functions, which are of great value in the field of new drug research and development. The researches on the detection and assay methods of shikimic acid in Ginkgo biloba L., the preparation, pharmacological effects and applications in the synthesis of new compounds are reviewed in this paper, which provide a reference for the further development and utilization of shikimic acid resources.
Compound N-Boc-dopamine(13) prepared by protecting dopamine hydrochloride(12) with(Boc)2O was ethylated with diethyl sulfate to obtain tert-butyl (3,4-diethyloxyphenylethyl) carbamate(14), and then 14 was hydrolyzed to obtain 3,4-diethyloxyphenylethylamine(4). In addition, 1,2-diethoxybenzene(16) was obtained by ethylation of catechol(15) with diethyl sulfate. Ethyl 2-(3,4-diethoxyphenyl)-2-oxoacetate(17) was prepared by Friedel-Crafts acylation of compound 16. The key intermediate 2-(3,4-diethoxyphenyl)acetic acid(5) was obtained from compound 17 by Huangminglong reaction in the presence of KOH / hydrazine hydrate. The acyl chloride compound of 5 was condensed with compound 4 for a further cyclization reaction to obtain drotaverine hydrochloride(1) with an overall yield of 60.4% (based on 12). The synthetic route was simple, safe and easy to operate, without high temperature, high pressure and highly toxic raw materials, and it was suitable for industrial production.
To perform the quality control of lorcaserin hydrochloride, five related substances were prepared. These substances were 8-chloro-3-(2-chloropropyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine(A), (R)-8-chloro-1-methyl-3-acetyl-1,2,4,5-tetrahydro-1H-benzo[d]azepine(B), (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]-azepine (2S,3S)-2,3-dihydroxysuccinate(2∶1)(C), (R)-7-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride(D), (S)-7-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride(E). The related substances A, D and E have not been reported in literature. The structures of the above related substances were confirmed by 1H NMR and MS, and the substitution position of chlorine atom as well as chiral configuration of related substance D was confirmed by single crystal X-ray diffraction, which could be used as references of lorcaserin hydrochloride quality control.
A new human promyelocytic leukemia(HL-60)/nuclear factor-κB(NF-κB) reporter gene pyrogen detection method was established initially, and its application in pyrogen detection in adalimumab injection, bevacizumab injection, tocilizumab injection and daratumumab injection was discussed. And the accuracy, repeatability and sensitivity of this method were validated. The lipopolysaccharide(LPS) standard solutions with different concentrations were prepared to act on the cells under the minimum dilution factor of the four monoclonal antibody injections without interference. The logarithmic value of LPS concentration was taken as the abscissa and the chemiluminescence intensity value was taken as the ordinate, and a standard curve was fitted. The results showed that the R2 values were all greater than 0.950 0. When the concentration of LPS standard was greater than 1 EU/ml, the coefficient of variation was less than 20%, and the average detection limit of this method was 0.02 EU/ml, which provided a reference for the expansion of the pyrogen detection method for biological products.
Taking BAMA piglet as the experimental animal model, the dermato-pharmacokinetic properties of terbinafine hydrochloride film-forming system and the commercially available product(1% terbinafine hydrochloride cutaneous solution) were preliminarily investigated by the tape stripping method. An HPLC and a LC/MS were established for determination of drug concentration in the stratum corneum peeled off from the piglet skin on days 0 - 7 and days 7 - 14 after administration, respectively. The results showed that there were no significant differences between the self-made and reference preparations in main pharmacokinetic parameters(P>0.05). The values of cmax, t1/2 and AUC0→t for the self-made and reference preparations were (14 603.95±1 461.59) and (14 542.08±1 481.07)ng/cm2,(75.84±22.35) and (68.34±3.41)h, (920 447.88±166 949.76) and (901 108.6±141 669.28)ng·cm–2·h, respectively. The values of tmax for both preparations were 3 h. The relative bioavailability of the self-made preparation was (102.15±15.13)%.
The release behaviors of docetaxel from a series of Poloxamer188 composite poly L-lactic acid electrospun fibers and the effect of drug incorporation amount on its release behavior were investigated. Docetaxel, poloxamer 188 and poly L-lactic acid were all dissolved in dichloromethane to form a homogeneous solution. The composite amount of poloxamer 188 and the loading amount of docetaxel were set as 220%, 240%, 260%, 280% and 300% of the mass of poly L-lactic acid, and 5%, 10% and 15% of the mass of poly L-lactic acid. Then, a series of electrospun fibers incorporated with docetaxel were prepared by electrospinning. The observation results of scanning electron microscopy revealed that all the products were micro-scale fibers with uniform diameter and without beads structure. The results of X-ray diffraction, differential thermal analysis and infrared spectroscopy showed that docetaxel was well combined within the fibers, while poloxamer 188 separated on the fiber surfaces. By measuring the release amount of docetaxel from electrospun fibers in pure water, the release curves were drawn, and the release data obtained could be fitted with the similar form of Lagergren equation. The results also showed that docetaxel was of being solubilized during the whole release process. As poloxamer 188 composite content increased, the drug release amount slightly increased. As docetaxel loading amount increased, the drug release amount decreased significantly. When composite amount of poloxamer 188 was 300% and the loading amount of docetaxel was 5%, cumulative release of the drug at 672 h in pure water was 59.36%, and its absolute release was 7.3 μg/mg fiber.
The liposomes loaded with diosmetin were prepared by thin film ultrasonic dispersion method to improve poor water-soluble of diosmetin. With encapsulation efficiency and particle size as main indicators, single factor tests were carried out to find the test ranges of formulation and process parameters, followed by further optimization with response surface methodology coupled with Box-Behnken design. The optimal formulation and process parameters were as follows: lipid-drug ratio(namely the mass ratio of soybean phospholipids to diosmetin) was 5.26, cholesterol mass was 6.31 mg, and phospholipid concentration after hydration was 1.19 mg/ml, ultrasonic treatment of the obtained hydration liquid was conducted at 360 W for 2 min. The particle size, ζ potential, encapsulation efficiency and drug loading of the final diosmetin liposomes were (146±3)nm, (–38.63±0.13)mV, (88.2±1.2)% and 14.6%, respectively. The transmission electron microscopy analysis revealed that the liposomes were uniform in size and spherical in shape. The in vitro cumulative release at 48 h was 79.68%, and the diosmetin release behavior was conformed to the Weibull's equation(r=0.995 0).